The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison
Open Access
- 21 April 2005
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 19 (6) , 916-920
- https://doi.org/10.1038/sj.leu.2403770
Abstract
Using a genetic randomization through a ‘donor’ vs ‘no donor’ comparison, the aim of this analysis was to assess the real benefit of reduced intensity conditioning allogeneic stem cell transplantation (RIC-allo-SCT) among 95 adult high-risk acute myeloid leukemia (AML) patients. In an ‘intention-to-treat’ analysis, leukemia-free survival (LFS) was significantly higher in the ‘donor’ group as compared to the ‘no donor’ group (P=0.01; 54 vs 30% at 4 years). The latter held true when restricting the analysis to the 25 patients who could actually receive the RIC-allo-SCT (P=0.001). Overall transplant-related mortality in the ‘transplant’ group was 12%, with overall survival (OS) being significantly higher in the ‘transplant’ group as compared to the ‘no transplant’ group (P=0.01). Also, in the ‘intention-to-treat’ analysis, OS was significantly higher in the ‘donor’ group as compared to the ‘no donor’ group (P=0.04). In the multivariate analysis, actual performance of RIC-allo-SCT (P=0.001; RR=4.0; 95% CI, 1.7–9.6) was the strongest factor significantly predictive of an improved LFS. We conclude that if a matched related donor is identified, RIC-allo-SCT should be proposed for AML patients not eligible for standard myeloablative allo-SCT.Keywords
This publication has 24 references indexed in Scilit:
- Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donorsBlood, 2004
- Myeloablative conditioning regimens for AML allografts: 30 years laterBone Marrow Transplantation, 2003
- Durable Remissions of Myelodysplastic Syndrome and Acute Myeloid Leukemia After Reduced-Intensity AllograftingJournal of Clinical Oncology, 2003
- Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimenLeukemia, 2003
- Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin–based reduced-intensity preparative regimenBlood, 2003
- Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trialBlood, 2003
- Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromesBlood, 2002
- Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First RemissionNew England Journal of Medicine, 1998
- The influence of HLA‐matched sibling donor availability on treatment outcome for patients with AML: an analysis of the AML 8A study of the EORTC Leukaemia Cooperative Group and GIMEMABritish Journal of Haematology, 1998
- Autologous or Allogeneic Bone Marrow Transplantation Compared with Intensive Chemotherapy in Acute Myelogenous LeukemiaNew England Journal of Medicine, 1995